Fig. 2From: Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancerPrognostic value of MTOR in CRC patients. A, B Kaplan–Meier survival curve comparing high (N = 279) and low (N = 280) MTOR expression determined by the median value and high (N = 140) and low (N = 140) MTOR expression determined by quantile value for the TCGA CRC patient cohort. C, D Kaplan–Meier survival curve comparing high (N = 95) and low (N = 96) MTOR expression determined by the median value and high (N = 47) and low (N = 47) MTOR expression determined by quantile value for the CRC patients in the GSE87211 database. CRC, colorectal cancer; TCGA, The Cancer Genome AtlasBack to article page